PriceTargets.com logo

Tenaya Therapeutics - TNYA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.33
  • Forecasted Upside: 398.08%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$3.48 As of 12/3/2024 12:51 PM ET
▼ -0.1 (-2.79%)

This chart shows the closing price for TNYA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tenaya Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TNYA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNYA

Analyst Price Target is $17.33
▲ +398.08% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Tenaya Therapeutics in the last 3 months. The average price target is $17.33, with a high forecast of $18.00 and a low forecast of $16.00. The average price target represents a 398.08% upside from the last price of $3.48.

This chart shows the closing price for TNYA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Tenaya Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
11/7/2024Chardan CapitalLower TargetBuy ➝ Buy$20.00 ➝ $18.00
10/18/2024Piper SandlerReiterated RatingOverweight ➝ Overweight
10/18/2024Leerink PartnersReiterated RatingOutperform ➝ Outperform
10/18/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
10/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
7/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
6/10/2024William BlairInitiated CoverageOutperform
5/16/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$18.00 ➝ $16.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00
3/21/2024Chardan CapitalReiterated RatingBuy ➝ Buy$20.00
3/20/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$19.00 ➝ $18.00
3/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00
11/30/2023Leerink PartnrsReiterated RatingOutperform
11/30/2023Leerink PartnersInitiated CoverageOutperform$7.00
10/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$18.00
8/14/2023Chardan CapitalReiterated RatingBuy ➝ Buy$23.00
8/11/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$18.00 ➝ $17.00
8/10/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$13.00 ➝ $14.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$18.00
8/8/2023Lifesci CapitalReiterated RatingOutperform
5/11/2023Chardan CapitalLower Target$24.00 ➝ $23.00
3/9/2023Chardan CapitalLower TargetBuy$28.00 ➝ $24.00
3/9/2023HC WainwrightLower TargetBuy$25.00 ➝ $18.00
1/24/2023Morgan StanleyLower TargetOverweight$15.00 ➝ $13.00
11/11/2022Chardan CapitalLower TargetBuy$30.00 ➝ $28.00
11/8/2022Canaccord Genuity GroupInitiated CoverageBuy$21.00
11/7/2022Canaccord Genuity GroupInitiated CoverageBuy
8/11/2022Chardan CapitalLower TargetBuy$31.00 ➝ $30.00
6/16/2022Lifesci CapitalReiterated RatingOutperform
6/15/2022HC WainwrightInitiated CoverageBuy$25.00
1/17/2022Chardan CapitalReiterated RatingBuy
8/24/2021Chardan CapitalInitiated CoverageBuy$37.00
8/24/2021Morgan StanleyInitiated CoverageOverweight$31.00
8/24/2021CowenInitiated CoverageOutperform
8/24/2021Piper SandlerInitiated CoverageOverweight$40.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 11 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 11 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Tenaya Therapeutics logo
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $3.48
Low: $3.21
High: $3.60

50 Day Range

MA: $2.14
Low: $1.64
High: $3.57

52 Week Range

Now: $3.48
Low: $1.61
High: $7.01

Volume

2,190,666 shs

Average Volume

1,049,823 shs

Market Capitalization

$275.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Tenaya Therapeutics?

The following Wall Street analysts have issued reports on Tenaya Therapeutics in the last twelve months: Canaccord Genuity Group Inc., Chardan Capital, HC Wainwright, Leerink Partners, Piper Sandler, and William Blair.
View the latest analyst ratings for TNYA.

What is the current price target for Tenaya Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Tenaya Therapeutics in the last year. Their average twelve-month price target is $17.33, suggesting a possible upside of 398.1%. Chardan Capital has the highest price target set, predicting TNYA will reach $18.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $16.00 for Tenaya Therapeutics in the next year.
View the latest price targets for TNYA.

What is the current consensus analyst rating for Tenaya Therapeutics?

Tenaya Therapeutics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TNYA will outperform the market and that investors should add to their positions of Tenaya Therapeutics.
View the latest ratings for TNYA.

What other companies compete with Tenaya Therapeutics?

Other companies that are similar to Tenaya Therapeutics include Septerna, Gyre Therapeutics, Avadel Pharmaceuticals, Bicara Therapeutics and Cogent Biosciences. Learn More about companies similar to Tenaya Therapeutics.

How do I contact Tenaya Therapeutics' investor relations team?

The company's listed phone number is 650-825-6990 and its investor relations email address is [email protected]. The official website for Tenaya Therapeutics is www.tenayatherapeutics.com. Learn More about contacing Tenaya Therapeutics investor relations.